ArticleBiotechnology, biotechnological equipment2014
Colorectal cancer severity and survival in correlation with tumour necrosis factor-alpha.
Article in Biotechnology, biotechnological equipment, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Associations of tumor necrosis factor-α polymorphisms with the risk of colorectal cancer: a meta-analysis.Bioscience reports · 2019Pooled it
- A trial sequential meta-analysis ofBioscience reports · 2019Pooled it
- Elevated TNF-α level is correlated with NF-κB/p65 activation in patients with sporadic colorectal cancer.Molecular and clinical oncology · 2026Article
- Article
- Integrated transcriptomic profiling reveals immune and molecular stage-specific signatures of colorectal cancer in hispanics living in Puerto Rico.Frontiers in immunology · 2026Article
- Targeting cytokine and chemokine signaling pathways for enhancing chemo-sensitivity in colorectal cancer.Cell communication and signaling : CCS · 2025Review
- Tumor Necrosis Factor-Alpha's Role in the Pathophysiology of Colon Cancer.Diseases (Basel, Switzerland) · 2025Review
- Integrating TNF-α with Established Tumor Markers to Enhance Prognostic Accuracy in Gastric Cancer: A Prospective Observational Study.Biomedicines · 2025Article
- Study the Impact of NADPH oxidase1,TNF-alpha and Cyclooxygenase-2 On Colon Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Helminth-induced immune modulation in colorectal cancer: exploring therapeutic applications.Frontiers in immunology · 2025Review
- Biomarkers of inflammation and colorectal cancer risk.Frontiers in oncology · 2025Review
- Article
- NF-κB pathway and angiogenesis: insights into colorectal cancer development and therapeutic targets.European journal of medical research · 2024Review
- Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid cultures.Journal for immunotherapy of cancer · 2024Article
- Tumor-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signaling.iScience · 2024Article
- CSER: a gene regulatory network construction method based on causal strength and ensemble regression.Frontiers in genetics · 2024Article
- Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring.Journal of clinical medicine · 2023Review
- Tumor necrosis factor-α induces proliferation and reduces apoptosis of colorectal cancer cells through STAT3 activation.Immunogenetics · 2023Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) development is strongly associated with innate immune mechanisms and intestinal inflammation. The aim of the study was to investigate the pre-operative serum levels of TNF-α and its correlation with cancer progression and survival in CRC patients taking into account the genotype of -308G/A promoter polymorphism in TNF-α gene (rs1800629). TNF-α -308G/A genotypes of 119 CRC cases and 177 no CRC controls were determined by restriction fragment length polymorphism assay (RFLP-PCR). TNF-α serum levels were measured by enzyme-linked immunosorbent assay (ELISA). Although no significant differences in allele and genotype frequencies between CRC and controls were observed, it should be noted that the minor allele-A and its homozygous genotype were overrepresented among CRC. In addition, allele-A was more frequent in early CRC patients compared to advanced cases. TNF-α serum level was significantly higher in CRC patients than in controls (36.1 ± 8.4 pg/mL vs. 18.66 ± 11 pg/mL;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.